Feasibility and clinical decision-making with 3D echocardiography in routine practice

Standard 2D echocardiography is widely used to assess left ventricular function, but it may have limitations in accuracy. Prior research has shown that 2D methods can misclassify patients near critical thresholds for treatment decisions. No prior work had resolved whether adding 3D echocardiography in routine practice could improve diagnostic precision. This gap motivated a study to evaluate whether 3D echocardiography could be used routinely and whether it could change clinical categorization. It was already known that 3D imaging could offer more accurate volume measurements in controlled settings. That uncertainty drove the need to test feasibility and impact in unselected patients. The question remained whether 3D echocardiography could be integrated into standard practice without excessive time costs. This study aimed to address those uncertainties in a real-world clinical setting.

The study aimed to evaluate whether 3D echocardiography could be used routinely in clinical practice and whether it could influence clinical decisions. Researchers focused on left ventricular ejection fraction and volumes, which are key indicators for treatment decisions. The motivation came from the need to improve diagnostic accuracy for patients near critical thresholds. The study tested whether 3D echocardiography could be acquired and measured efficiently in a broad patient group. It also sought to determine whether 3D measurements would lead to different clinical categorizations than 2D methods. The researchers proposed that 3D imaging could provide more precise measurements in real-world conditions. They wanted to assess whether the added time for 3D imaging was acceptable in routine practice. The goal was to determine if 3D echocardiography could be a valuable addition to standard assessments.

The study involved patients undergoing echocardiography at three hospital-based labs. A feasibility group of 168 unselected patients received both 2D and 3D imaging. An expanded group of 220 patients was used to assess clinical impact. Feasibility was defined as the ability to measure left ventricular parameters with 3D. The researchers evaluated four clinical thresholds related to volume and ejection fraction. Time for 3D acquisition and measurement was recorded in 184 patients. The study compared 2D and 3D results to see how often categorizations changed. Researchers tracked how many patients were reclassified into different treatment groups. The study focused on whether 3D imaging could alter clinical decisions in real-world settings.

3D echocardiography was technically feasible in 83% of unselected patients. The additional time for 3D acquisition and measurement averaged 5.4 minutes per case. 3D imaging changed patient categorization in 6-11% of cases across four thresholds. For LVEF <35%, 17.5% of patients were reallocated based on 3D data. For LVEF <40%, 16.1% of patients were reclassified. For LVESV >30 ml/m², 12.4% of patients were moved to a different category. For LVESV >50 ml/m², 8.5% of patients had altered classifications. Most changes occurred within 10 ml/m² of volume thresholds and 10% of ejection fraction thresholds. These findings suggest that 3D imaging could impact treatment decisions in a significant subset of patients.

The authors proposed that 3D echocardiography is feasible in a large proportion of unselected patients. They suggested that the additional time required for 3D imaging is acceptable in routine practice. The study suggested that 3D imaging could lead to meaningful changes in clinical categorization. The authors proposed that the greatest impact occurs near critical volume and ejection fraction thresholds. They suggested that 3D imaging could help avoid misclassification in patients close to treatment guidelines. The findings suggest that 3D echocardiography could improve diagnostic accuracy in real-world settings. The authors proposed that integrating 3D imaging into routine practice could enhance clinical decision-making. They suggested that further study is needed to confirm the long-term benefits of 3D echocardiography in clinical settings.